FTSE 100 news / Companies and sectors / GSK / 6 October 2026

GSK (GSK): news on Tuesday 6 October 2026

+4.7 positive

Coverage was mildly positive, led by a Health Canada review of Jemperli for rectal cancer, a ViiV investment in paediatric HIV response and discussion of the Nuvalent acquisition as a growth prospect. Q2 sales growth was tempered by a profit hit, and the shares were flat.

What drove it

Jemperli regulatory review
Nuvalent acquisition
Q2 results

The 6 stories

Each headline's own score, strongest first. Links go to the publisher.

+7.5 GSK’s Jemperli (dostarlimab) accepted for review by Health Canada for patients with dMMR/MSI-H locally advanced rectal cancer Bioscience Association Manitoba
Health Canada accepted Jemperli rectal cancer application for review
+6.7 ViiV HEALTHCARE MAKES NEW £9.75 MILLION INVESTMENT TO ACCELERATE HIV RESPONSE FOR PAEDIATRIC AND ADOLESCENT POPULATION Bioscience Association Manitoba
ViiV investment in paediatric HIV response supports reputation
+5.0 Can FTSE 100 Drugmaker (LSE:GSK) Turn Its Nuvalent Acquisition Into A Fresh Growth Engine After This Week's Deal News? Kalkine Media
Nuvalent acquisition viewed as possible growth engine
+1.7 GSK stock reports Q2 sales growth despite profit hit AD HOC NEWS
Q2 sales growth offset by profit hit
+0.8 Expert View: GSK, IP Group, Tatton, Plus500, Ithaca Energy Citywire
GSK among stocks in analyst commentary; little detail
0.0 Why is GSK stock flat today? Resistance levels in focus Traders Union
Flat share price, technical commentary only

GSK: every day · Pharma and healthcare on 6 October 2026 · FTSE 100 overview for the day